Analysis of Segments and Major Growth Areas in the Drug-Coated Balloons Market

The drug-coated balloons market is poised for significant expansion in the coming years, driven by advancements in vascular treatment options and increasing adoption of innovative technologies. This sector is becoming a focal point for medical professionals seeking effective, less invasive therapies for cardiovascular conditions. Below is a detailed overview of the market size, key players, emerging trends, and segment-wise insights shaping the future of drug-coated balloons.

Projected Growth and Size of the Drug-Coated Balloons Market
The drug-coated balloons market is anticipated to experience rapid growth, reaching a valuation of $2.55 billion by 2030. This represents a strong compound annual growth rate (CAGR) of 15.6%. The surge in market size is largely due to the growing use of drug-coated balloon (DCB) therapies in coronary artery applications, increasing incorporation of next-generation coating technologies, expansion in catheter-based procedures, heightened investment in vascular innovation, and a rising preference for treatment choices that avoid stents. Key growth trends expected during the forecast include wider adoption of sirolimus-coated balloons, increased use in peripheral artery disease management, a shift toward minimally invasive vascular treatments, advances in drug-coating technology, and an emphasis on enhancing drug delivery efficiency.

Download a free sample of the drug-coated balloons market report:
https://www.thebusinessresearchcompany.com/report/drug-coated-balloons-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Driving the Drug-Coated Balloons Market
Several prominent companies are making significant contributions to the drug-coated balloons industry. These include Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, B. Braun Melsungen AG, Terumo Corporation, Biotronik SE & Co. KG, Biosensors International Group Ltd, Concept Medical Inc., Acotec Scientific AG, Cardionovum GmbH, MedAlliance SA, iVascular SLU, Minvasys SAS, QT Vascular Ltd, Hexacath SAS, Cordis Corporation, MicroPort Scientific Corporation, Endocor GmbH, Orchestra BioMed Inc., Lepu Medical Technology Co. Ltd, Balton Sp. z o.o., and BrosMed Medical Co. Ltd.

Notably, in October 2023, Cordis US Corp, a U.S.-based manufacturer specializing in interventional cardiovascular technologies, acquired Switzerland-based MedAlliance SA for an undisclosed sum. This acquisition aims to integrate MedAlliance's SELUTION SLR sirolimus micro-reservoir drug-coated balloon into Cordis's coronary and peripheral product lines, thereby accelerating market penetration, expanding clinical research, and broadening treatment options for patients suffering from coronary and peripheral vascular diseases.

View the full drug-coated balloons market report:
https://www.thebusinessresearchcompany.com/report/drug-coated-balloons-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Technological Advances and Trends Shaping the Drug-Coated Balloons Industry
Market leaders are heavily investing in enhancing drug-coated balloon technology to improve treatment outcomes, especially for coronary in-stent restenosis (ISR). One key innovation is the development of paclitaxel-coated balloon catheters, which deliver the drug paclitaxel directly to artery walls during inflation, effectively preventing artery re-narrowing following angioplasty. These advances aim to reduce complications typically associated with conventional therapies and optimize patient recovery.

For example, in March 2024, Boston Scientific Corporation received approval from the U.S. Food and Drug Administration (FDA) for its AGENTTM Drug-Coated Balloon (DCB). This device targets coronary ISR in patients with coronary artery disease, offering an innovative treatment for blood vessels that become blocked or narrowed due to plaque or scar tissue buildup after stenting.

Detailed Market Segmentation of Drug-Coated Balloons
The drug-coated balloons market is segmented by product, drug type, and end user, with further subcategories within each group:

By Product:
- Drug-Coated Balloons for Peripheral Artery Disease
- Drug-Coated Balloons for Coronary Artery Disease

By Drug Type:
- Paclitaxel
- Sirolimus

By End User:
- Hospitals
- Cardiac Catheterization Labs
- Ambulatory Surgical Centers

Subsegments are also defined for the specific application of drug types within the peripheral and coronary artery disease categories, including paclitaxel-coated and sirolimus-coated balloons for both disease types.

This structured segmentation allows for a focused understanding of market demands and opportunities in different therapeutic areas and healare settings.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.